ArticleScientific reports2025
Dual role of ROS-dependent anti-cancer activity and photocatalytic degradation of graphene oxide against MCF-7 breast cancer cells and organic dye.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Green Fabrication and Characterization of Copper Oxide Nanoparticles Using C. Gigantea Leaf Extract and Their ROS-Mediated Anticancer Activity Against A549 Lung Cancer Cells.Cell biochemistry and biophysics · 2026Article
Corrections and comments
- Retracted
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graphene oxide (GO), a two-dimensional nanomaterial, was synthesized using a modified Hummers' method and evaluated for its dual biomedical and environmental applications. Structural characterization confirmed the successful formation of GO, as evidenced by XRD (d-spacing of 10.23 Å), FTIR (hydroxyl, epoxy, carboxyl, and carbonyl functional groups), TGA (distinct weight loss patterns), and microscopic analyses (FE-SEM, EDX, and HR-TEM) revealing spherical and rod-like morphologies. Biologically, GO exhibited potent cytotoxicity against MCF-7 breast cancer cells in a concentration-dependent manner. The IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.